Late-breaking and deferred publication abstractsGenitourinary tumours, non-prostateLBA5 - CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups
Genitourinary tumours, non-prostate
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2017 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.